// App-Quantinova.ai

FRI0128 (2018) : Integrated safety data analysis across phase 3 clinical studies for intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Researchers

Presenter

  • M.E. Husni

Principal Investigators

  • S. Schwartzman

  • A. Deodhar

  • S. Kafka

  • S.D. Chakravarty

  • E.C. Hsia

  • D.D. Harrison

  • J.H. Leu

  • Y. Zhou

  • K.H. Lo

  • A. Kavanaugh

Medical Centers

  • Cleveland Clinic, Cleveland, OH

  • Weill Cornell Medical College, New York, NY

  • Oregon Health and Science University, Portland, OR

  • Janssen Scientific Affairs, LLC

  • Janssen Scientific Affairs, LLC/Drexel U School of Medicine, Horsham/Phila, PA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Horsham, PA

  • Janssen Research and Development, LLC, Spring House, PA

  • UCSD, San Diego, CA

Locations

  • United States

  • United Kingdom

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

  • Rheumatoid arthritis

  • Psoriatic arthritis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • golimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved